獣医用モノクローナル抗体市場規模、セグメント分析、2030年までの世界予測

本レポートは、動物種、製品、治療領域、投与経路、エンドユーザー、地域に基づいて、獣医用モノクローナル抗体市場を分析しています。また、市場の成長に影響を与える推進要因や制約要因なども考察しています。本レポートは、市場における機会と課題を明らかにし、市場リーダーの競争環境に関する詳細な情報を提供しています。さらに、ミクロ市場を個々の成長傾向に基づいて分析し、5つの主要地域とそれぞれの国における市場セグメントの収益予測も行っています。

本レポートは、既存企業だけでなく新興企業や小規模企業にとっても、市場動向を理解し、市場シェアの拡大に役立てることができます。本レポートをご購入いただいた企業は、以下の5つの戦略のいずれか、または組み合わせて活用することができます。

世界の獣医用モノクローナル抗体市場は、2025年の17億米ドルから2030年には30億6,000万米ドルに達し、年平均成長率（CAGR）12.4%で成長すると予測されています。市場は、コンパニオンアニマル人口の増加とペット飼育数の増加に牽引され、著しい成長を遂げています。慢性疾患への懸念の高まりも、獣医治療の需要をさらに押し上げています。政府や動物福祉団体は、ペットと家畜の両方において、皮膚疾患の早期診断と治療を促す啓発キャンペーンを積極的に展開しています。しかしながら、市場はペットケア費用の高騰など、治療の採用を制限する可能性のある課題に直面しています。さらに、厳格な規制ガイドラインと医薬品の承認期間の長さも、市場の成長を抑制しています。これらのハードルにもかかわらず、皮膚科や変形性関節症以外の治療適応の拡大は、新たな市場機会を創出し続けています。

The global veterinary monoclonal antibodies market is projected to reach USD 3.06 billion by 2030, from USD 1.70 billion in 2025, with a CAGR of 12.4%. The market is experiencing significant growth, driven by the expanding companion animal population and rising pet ownership. Growing concerns about chronic diseases have further boosted the demand for veterinary treatments. Government and animal welfare organizations actively promote awareness campaigns, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals. However, the market faces challenges such as rising pet care costs, which can limit treatment adoption. Furthermore, strict regulatory guidelines and lengthy approval times for drugs further restrain market growth. Despite these hurdles, expanding therapeutic indications beyond dermatology and osteoarthritis continues to create new market opportunities.

“By animal type, the canine segment held the highest share in 2024.”

The canine segment held the largest market share in 2024, driven by rising pet dog ownership and increasing spending on animal healthcare. Dogs are highly prone to skin conditions such as allergies, fungal infections, and ectoparasitic infestations, which require frequent dermatological treatments. The growing trend of pet humanization and the demand for premium veterinary care further support market growth. Additionally, advancements in dermatological treatments, including biologics and targeted monoclonal antibody therapies, improve treatment outcomes for dogs, solidifying the segment’s dominance in the market.

“By route of administration, the subcutaneous segment is projected to record the highest CAGR between 2025 and 2030.”

The subcutaneous segment is expected to grow at the fastest rate during the forecast period due to its ease of administration and better pet owner compliance. Rising veterinary recommendations for systemic treatments over topical solutions and the ongoing development of new monoclonal antibodies targeting infectious diseases are increasing demand. Moreover, innovations in monoclonal antibodies targeting infectious diseases further support the segment’s growth in the veterinary monoclonal antibodies market.

“By product, cytopoint was the leading segment in 2024.”

The cytopoint segment held the largest market share in 2024, driven by its status as the first and only FDA- and EMA-approved monoclonal antibody therapy for treating canine atopic dermatitis. Additionally, the high prevalence of atopic dermatitis in dogs has increased demand for cytopoint due to its proven efficacy, safety profile, and rising adoption by veterinarians. The growing willingness of pet owners to invest in advanced veterinary treatments has further fueled market growth.

“By therapy type, dermatology surpassed other segments in 2024.”

The dermatology segment held the largest market share in 2024 due to the rising prevalence of chronic diseases such as atopic dermatitis in dogs. Additionally, growing awareness of advanced treatment options like Cytopoint by Zoetis (US) has gained significant traction due to its long-lasting relief and minimal side effects in treating allergic and atopic dermatitis in dogs. The willingness to spend on pet healthcare has further driven this market growth.

“By end user, veterinary hospitals/specialty centers are expected to exhibit the fastest growth during the forecast period.”

Veterinary hospitals/specialty centers are expected to grow at the fastest rate, fueled by the rise in veterinary visits and the availability of specialized pet healthcare services. These facilities offer comprehensive treatment options, including advanced diagnostics, prescription medications, and surgical procedures for various conditions. Additionally, pet insurance coverage for dermatological treatments encourages pet owners to seek veterinary care, boosting demand in this segment.

“North America accounted for the largest share in 2024.”

North America held the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in R&D for innovative monoclonal antibody therapies. Rising awareness about pet health, along with increasing spending on veterinary care, also drives market growth. The growing demand for premium pet care products further contributes to North America’s dominance in the global veterinary monoclonal antibodies market.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 – 75%, Tier 2 – 15%, and Tier 3 – 10%
• By Designation: C-level – 30%, D-level – 23%, and Other Designations – 47%
• By Region: North America – 35%, Europe – 20%, Asia Pacific – 25%, Latin America – 13%, and Middle East & Africa – 7%

The major players operating in the veterinary monoclonal antibodies market are Zoetis Services LLC (US), Elanco (US), and Merck & Co., Inc. (US).

Research Coverage

This report examines the veterinary monoclonal antibodies market based on animal type, product, therapy area, route of administration, end user, and region. It also considers factors such as drivers and restraints that influence market growth. The report highlights opportunities and challenges within the market and offers details about the competitive landscape for market leaders. Additionally, it analyzes micro markets concerning their individual growth trends and forecasts the revenue of market segments across five main regions and their respective countries.

Reasons to Buy this Report

The report can assist both established firms and new or smaller companies in understanding the market dynamics, which can help them increase their market share. Companies purchasing the report may employ one or a combination of the five strategies listed below.

This report provides insights into the following points:

• Analysis of key drivers (increased prevalence of chronic diseases in animals, innovation in monoclonal antibodies targeting infectious diseases, rise in companion animal population and pet ownership, growth in veterinary healthcare expenditure), restraints (regulatory hurdles and long approval timelines, high cost of development and treatment), opportunities (expanding therapeutic indications beyond dermatology and osteoarthritis, novel administration routes for monoclonal antibodies, rising strategic developments among market players in development of veterinary monoclonal antibodies), and challenges (emerging safety concerns and adverse events reporting, and limited species-specific knowledge) influencing the growth of veterinary monoclonal antibodies market
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the veterinary monoclonal antibodies market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of monoclonal antibody treatments across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary monoclonal antibodies market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary monoclonal antibodies market

Table of Contents

1               INTRODUCTION              25

1.1           STUDY OBJECTIVES       25

1.2           MARKET DEFINITION   25

1.3           STUDY SCOPE   26

1.3.1        MARKET SEGMENTATION AND REGIONAL SCOPE                 26

1.3.2        INCLUSIONS AND EXCLUSIONS 27

1.3.3        YEARS CONSIDERED      28

1.4           CURRENCY CONSIDERED            28

1.5           STAKEHOLDERS               28

2               RESEARCH METHODOLOGY       29

2.1           RESEARCH DATA              29

2.1.1        SECONDARY DATA          30

2.1.1.1    Key data from secondary sources       31

2.1.2        PRIMARY DATA 31

2.1.2.1    Primary sources    32

2.1.2.2    Key industry insights           33

2.1.2.3    Breakdown of primaries      33

2.2           MARKET SIZE ESTIMATION         35

2.2.1        REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)                 35

2.2.2        EPIDEMIOLOGY-BASED APPROACH        37

2.2.3        COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS      37

2.2.4        TOP-DOWN APPROACH                37

2.2.5        BOTTOM-UP APPROACH              38

2.2.6        PRIMARY INTERVIEWS  38

2.3           GROWTH RATE PROJECTION     39

2.4           DATA TRIANGULATION                40

2.5           RESEARCH ASSUMPTIONS           41

2.6           RESEARCH LIMITATIONS             41

2.7           RISK ANALYSIS  42

3               EXECUTIVE SUMMARY  43

4               PREMIUM INSIGHTS       48

4.1           VETERINARY MONOCLONAL ANTIBODIES MARKET OVERVIEW          48

4.2           NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE AND COUNTRY                 49

4.3           VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2025 VS. 2030        49

4.4           VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2025 VS. 2030 (USD MILLION)      50

4.5           VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)                 50

4.6           VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA,

2025 VS. 2030 (USD MILLION)      51

4.7           VETERINARY MONOCLONAL ANTIBODIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES            52

5               MARKET OVERVIEW       53

5.1           INTRODUCTION              53

5.2           MARKET DYNAMICS       53

5.2.1        DRIVERS               54

5.2.1.1    Increasing prevalence of chronic diseases in animals     54

5.2.1.2    Innovations in monoclonal antibodies targeting infectious diseases  54

5.2.1.3    Rise in companion animal population and pet ownership                 55

5.2.1.4    Growth in veterinary healthcare expenditure  56

5.2.2        RESTRAINTS      56

5.2.2.1    Regulatory hurdles and long approval timelines              56

5.2.2.2    High cost of development and treatment          57

5.2.3        OPPORTUNITIES              58

5.2.3.1    Expanding therapeutic indications beyond dermatology and osteoarthritis         58

5.2.3.2    Novel administration routes for monoclonal antibodies 58

5.2.3.3    Evolving landscape of strategic collaborations and acquisitions                 59

5.2.4        CHALLENGES    59

5.2.4.1    Emerging safety concerns and adverse event reporting 59

5.2.4.2    Limited species-specific knowledge  60

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            60

5.4           PRICING ANALYSIS          61

5.4.1        INDICATIVE SELLING PRICE, BY KEY PLAYER     61

5.4.2        INDICATIVE SELLING PRICE, BY REGION              62

5.5           SUPPLY CHAIN ANALYSIS             63

5.6           ECOSYSTEM ANALYSIS  64

5.7           INVESTMENT AND FUNDING SCENARIO               65

5.8           TECHNOLOGY ANALYSIS             66

5.8.1        KEY TECHNOLOGIES     66

5.8.1.1    Hybridoma technology        66

5.8.1.2    Recombinant antibody production    67

5.8.2        COMPLEMENTARY TECHNOLOGIES       67

5.8.2.1    Long-acting injectables       67

5.8.3        ADJACENT TECHNOLOGIES       68

5.8.3.1    RNA-based therapies           68

5.9           PATENT ANALYSIS          68

5.9.1        PATENT PUBLICATION TREND 68

5.9.2        JURISDICTION AND TOP APPLICANT ANALYSIS                 69

5.10         TRADE ANALYSIS             71

5.10.1      IMPORT DATA  71

5.10.2      EXPORT DATA  71

5.11         KEY CONFERENCES AND EVENTS, 2025–2026        72

5.12         REGULATORY LANDSCAPE         73

5.12.1      REGULATORY FRAMEWORK       73

5.12.1.1  North America      73

5.12.1.2  Europe   73

5.12.1.3  Asia Pacific            73

5.12.1.4  Latin America       74

5.12.1.5  Middle East & Africa            74

5.12.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             74

5.13         PORTER’S FIVE FORCES ANALYSIS           78

5.13.1      BARGAINING POWER OF SUPPLIERS       79

5.13.2      BARGAINING POWER OF BUYERS             79

5.13.3      THREAT OF NEW ENTRANTS      79

5.13.4      THREAT OF SUBSTITUTES          79

5.13.5      INTENSITY OF COMPETITIVE RIVALRY 79

5.14         KEY STAKEHOLDERS AND BUYING CRITERIA     80

5.14.1      KEY STAKEHOLDERS IN BUYING PROCESS           80

5.14.2      KEY BUYING CRITERIA  81

5.15         UNMET NEEDS/END-USER EXPECTATIONS         82

5.16         REIMBURSEMENT ANALYSIS      83

5.17         PIPELINE ANALYSIS        83

5.18         IMPACT OF AI/GEN AI IN VETERINARY MONOCLONAL ANTIBODIES MARKET   85

5.18.1      INTRODUCTION              85

5.18.2      MARKET POTENTIAL OF AI IN VETERINARY MONOCLONAL ANTIBODIES     85

5.18.3      AI USE CASES     85

5.18.4      KEY COMPANIES IMPLEMENTING AI      86

5.19         IMPACT OF 2025 US TARIFF         87

5.19.1      INTRODUCTION              87

5.19.2      KEY TARIFF RATES          88

5.19.3      PRICE IMPACT ANALYSIS             89

5.19.4      IMPACT ON COUNTRY/REGION                89

5.19.5      IMPACT ON END-USE INDUSTRIES          90

6               VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE    91

6.1           INTRODUCTION              92

6.2           CANINES              92

6.2.1        INCREASING PREVALENCE OF OSTEOARTHRITIS AND CANINE ATOPIC DERMATITIS TO BOLSTER GROWTH   92

6.3           FELINES               94

6.3.1        GROWING RECOGNITION OF OSTEOARTHRITIS IN CATS AND SUCCESSFUL LAUNCH OF SOLENSIA TO FUEL MARKET               94

6.4           OTHER ANIMALS              96

7               VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT           97

7.1           INTRODUCTION              98

7.2           LOKIVETMAB (CYTOPOINT)      98

7.2.1        INCREASING PREVALENCE OF ATOPIC DERMATITIS IN DOGS TO PROMOTE GROWTH  98

7.3           BEDINVETMAB (LIBRELA)           99

7.3.1        NEED FOR BETTER PAIN MANAGEMENT SOLUTIONS TO EXPEDITE GROWTH                99

7.4           FRUNEVETMAB (SOLENSIA)       101

7.4.1        ABILITY TO IMPROVE MOBILITY AND COMFORT IN AGING CATS TO AID GROWTH  101

7.5           CANINE PARVOVIRUS MONOCLONAL ANTIBODY (CPMA) 102

7.5.1        INCREASING ADOPTION OF CPMA BY VETERINARY CLINICS, SHELTERS, AND PET OWNERS TO SPUR MARKET                 102

7.6           GILVETMAB       102

7.6.1        GROWING TREND TOWARD PERSONALIZED, TARGETED TREATMENTS TO FUEL MARKET     102

7.7           OTHER PRODUCTS         103

8               VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION             104

8.1           INTRODUCTION              105

8.2           SUBCUTANEOUS ROUTE OF ADMINISTRATION                 105

8.2.1        EASE OF ADMINISTRATION AND LOWER RISK OF TISSUE DAMAGE TO FACILITATE GROWTH        105

8.3           INTRAVENOUS ROUTE OF ADMINISTRATION    107

8.3.1        GROWING USE OF IV IN EMERGENCY CASES AND ONCOLOGY TO BOOST MARKET              107

8.4           ORAL ROUTE OF ADMINISTRATION       109

8.4.1        RISING INNOVATIONS IN LIVESTOCK APPLICATIONS TO ENCOURAGE GROWTH          109

9               VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA 110

9.1           INTRODUCTION              111

9.2           DERMATOLOGY               111

9.2.1        FAVORABLE SAFETY PROFILE AND IMPROVED EFFICACY TO FOSTER GROWTH               111

9.3           PAIN MANAGEMENT      113

9.3.1        RISING NEED FOR ALTERNATIVE DRUG DELIVERY TO AUGMENT GROWTH      113

9.4           INFECTIOUS DISEASES 115

9.4.1        GROWING FOCUS ON REDUCED HOSPITALIZATION TO DRIVE MARKET 115

9.5           ONCOLOGY        115

9.5.1        INCREASING ADVANCEMENTS IN MONOCLONAL ANTIBODY THERAPIES TO ACCELERATE GROWTH         115

9.6           OTHER THERAPY AREAS               116

10            VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER            118

10.1         INTRODUCTION              119

10.2         VETERINARY HOSPITALS/SPECIALTY CENTERS 119

10.2.1      RISE IN NUMBER OF VETERINARY SPECIALISTS TO SPEED UP GROWTH        119

10.3         VETERINARY CLINICS    121

10.3.1      GROWING PET OWNERSHIP AND PET CARE SPENDING TO FUEL MARKET            121

10.4         VETERINARY RESEARCH & ACADEMIC INSTITUTES                 123

10.4.1      INCREASING COLLABORATIVE RESEARCH EFFORTS TO EXPEDITE GROWTH       123

10.5         OTHER END USERS         125

11            VETERINARY MONOCLONAL ANTIBODIES MARKET, BY REGION                127

11.1         INTRODUCTION              128

11.2         NORTH AMERICA             129

11.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 129

11.2.2      US           133

11.2.2.1  Strong R&D and early commercial adoption of monoclonal antibodies to drive market  133

11.2.3      CANADA               136

11.2.3.1  Growing pet adoption to drive market              136

11.3         EUROPE               139

11.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      139

11.3.2      GERMANY           142

11.3.2.1  Established veterinary infrastructure and high rate of pet ownership to aid growth      142

11.3.3      FRANCE                145

11.3.3.1  Growing companion animal population to drive market                 145

11.3.4      UK          148

11.3.4.1  Increasing pet ownership to drive the market  148

11.3.5      ITALY    151

11.3.5.1  Strong demand for advanced therapies for companion animals and livestock to augment growth       151

11.3.6      SPAIN    154

11.3.6.1  Ongoing research in veterinary biologics to spur growth                 154

11.3.7      NETHERLANDS 157

11.3.7.1  Emerging pet care sector to contribute to growth           157

11.3.8      REST OF EUROPE             160

11.4         ASIA PACIFIC     163

11.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 164

11.4.2      JAPAN   168

11.4.2.1  Increasing awareness about pet health and well-established pet insurance system to drive market       168

11.4.3      CHINA  171

11.4.3.1  Expanding pet market to fuel market                 171

11.4.4      INDIA    174

11.4.4.1  Growing pet adoption and veterinary shortage to drive market                 174

11.4.5      AUSTRALIA         177

11.4.5.1  Increased spending on veterinary care to support growth                 177

11.4.6      SOUTH KOREA  180

11.4.6.1  Increasing awareness and adoption of preventive healthcare measures to drive market    180

11.4.7      NEW ZEALAND 183

11.4.7.1  Rising awareness of skin disorders to expedite growth   183

11.4.8      REST OF ASIA PACIFIC   186

11.5         LATIN AMERICA                189

11.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 189

11.5.2      BRAZIL 192

11.5.2.1  Expanding large-scale livestock operations to boost market                 192

11.5.3      MEXICO                195

11.5.3.1  Increasing demand for targeted biologics in livestock and pets to drive market          195

11.5.4      REST OF LATIN AMERICA             198

11.6         MIDDLE EAST & AFRICA                201

11.6.1      GROWING NUMBER OF COMPANION AND FOOD-PRODUCING ANIMALS TO PROPEL MARKET       201

11.6.2      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 201

12            COMPETITIVE LANDSCAPE         205

12.1         INTRODUCTION              205

12.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            205

12.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET  205

12.3         REVENUE SHARE ANALYSIS, 2022–2024    207

12.4         MARKET SHARE ANALYSIS, 2024                 207

12.5         BRAND/PRODUCT COMPARISON             210

12.6         COMPANY VALUATION AND FINANCIAL METRICS                 211

12.6.1      COMPANY VALUATION 211

12.6.2      FINANCIAL METRICS      211

12.7         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 212

12.7.1      STARS   212

12.7.2      EMERGING LEADERS     212

12.7.3      PERVASIVE PLAYERS      212

12.7.4      PARTICIPANTS 212

12.7.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         214

12.7.5.1  Company footprint               214

12.7.5.2  Region footprint   214

12.7.5.3  Animal type footprint           215

12.7.5.4  Route of administration footprint      215

12.7.5.5  Therapy area footprint         216

12.8         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        216

12.8.1      PROGRESSIVE COMPANIES         216

12.8.2      RESPONSIVE COMPANIES            216

12.8.3      DYNAMIC COMPANIES  217

12.8.4      STARTING BLOCKS         217

12.8.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 218

12.8.5.1  Detailed list of key startups/SMEs    218

12.8.5.2  Competitive benchmarking of key startups/SMEs          218

12.9         COMPETITIVE SCENARIO             219

12.9.1      PRODUCT LAUNCHES AND APPROVALS               219

12.9.2      DEALS  220

12.9.3      EXPANSIONS     221

13            COMPANY PROFILES      222

13.1         KEY PLAYERS     222

13.1.1      ZOETIS SERVICES LLC    222

13.1.1.1  Business overview 222

13.1.1.2  Products offered   223

13.1.1.3  Recent developments           224

13.1.1.3.1                Product launches and approvals         224

13.1.1.3.2                Deals      225

13.1.1.4  MnM view              225

13.1.1.4.1                Key strengths        225

13.1.1.4.2                Strategic choices   225

13.1.1.4.3                Weaknesses and competitive threats 226

13.1.2      ELANCO               227

13.1.2.1  Business overview 227

13.1.2.2  Products offered   228

13.1.2.3  Recent developments           229

13.1.2.3.1                Product launches and approvals         229

13.1.2.3.2                Expansions             229

13.1.2.4  MnM view              230

13.1.2.4.1                Key strengths        230

13.1.2.4.2                Strategic choices   230

13.1.2.4.3                Weaknesses and competitive threats 230

13.1.3      MERCK & CO., INC.          231

13.1.3.1  Business overview 231

13.1.3.2  Products offered   232

13.1.3.3  Recent developments           233

13.1.3.3.1                Product launches and approvals         233

13.1.3.3.2                Expansions             233

13.1.3.4  MnM view              234

13.1.3.4.1                Key strengths        234

13.1.3.4.2                Strategic choices   234

13.1.3.4.3                Weaknesses and competitive threats 234

13.1.4      ANIMAB                235

13.1.4.1  Business overview 235

13.1.4.2  Products offered   235

13.1.4.3  Recent developments           236

13.1.4.3.1                Deals      236

13.2         OTHER PLAYERS              237

13.2.1      VAXXINOVA INTERNATIONAL B.V.          237

13.2.2      CEVA LOGISTICS              238

13.2.3      MABGENESIS INC.            239

13.2.4      DECHRA               240

13.2.5      BIOGENESIS BAGO          241

13.2.6      BOEHRINGER INGELHEIM INTERNATIONAL GMBH                 242

13.2.7      VIRBAC 243

13.2.8      BIOVETA, A.S.    244

13.2.9      NIPPON ZENYAKU KOGYO CO., LTD.      245

14            APPENDIX           246

14.1         DISCUSSION GUIDE        246

14.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                249

14.3         CUSTOMIZATION OPTIONS        251

14.3.1      PRODUCT ANALYSIS      251

14.3.2      COMPANY INFORMATION           251

14.3.3      GEOGRAPHIC ANALYSIS               251

14.3.4      REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS            251

14.3.5      COUNTRY-LEVEL VOLUME ANALYSIS    251

14.3.6      BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)             251

14.3.7      ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST            251

14.4         RELATED REPORTS         252

14.5         AUTHOR DETAILS           253

LIST OF TABLES

TABLE 1                VETERINARY MONOCLONAL ANTIBODIES MARKET: INCLUSIONS AND EXCLUSIONS             27

TABLE 2                VETERINARY MONOCLONAL ANTIBODIES MARKET: RESEARCH ASSUMPTIONS       41

TABLE 3                VETERINARY MONOCLONAL ANTIBODIES MARKET: RISK ANALYSIS              42

TABLE 4                PET (DOGS AND CATS) OWNERSHIP IN US, 2024                 55

TABLE 5                INDICATIVE SELLING PRICE OF VETERINARY MONOCLONAL ANTIBODIES,

BY KEY PLAYER, 2024 (USD)         61

TABLE 6                INDICATIVE SELLING PRICE OF VETERINARY MONOCLONAL ANTIBODIES,

BY REGION, 2022–2024 (USD)      62

TABLE 7                VETERINARY MONOCLONAL ANTIBODIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM                65

TABLE 8                VETERINARY MONOCLONAL ANTIBODIES MARKET: INNOVATIONS AND

PATENT REGISTRATIONS, 2023–2024       70

TABLE 9                IMPORT DATA FOR HS CODE 300214, BY COUNTRY,

2021–2024 (USD THOUSAND)      71

TABLE 10              EXPORT DATA FOR HS CODE 300214, BY COUNTRY,

2021–2024 (USD THOUSAND)      71

TABLE 11              VETERINARY MONOCLONAL ANTIBODIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026   72

TABLE 12              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 74

TABLE 13              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           76

TABLE 14              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 77

TABLE 15              VETERINARY MONOCLONAL ANTIBODIES MARKET: PORTER’S FIVE FORCES ANALYSIS       78

TABLE 16              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER                81

TABLE 17              KEY BUYING CRITERIA, BY END USER    82

TABLE 18              VETERINARY MONOCLONAL ANTIBODIES MARKET: CURRENT UNMET NEEDS        82

TABLE 19              VETERINARY MONOCLONAL ANTIBODIES MARKET: PIPELINE ANALYSIS    83

TABLE 20              US-ADJUSTED RECIPROCAL TARIFF RATES                 88

TABLE 21              KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR VETERINARY MONOCLONAL ANTIBODIES MARKET                 88

TABLE 22              IMPACT ON COUNTRY/REGION DUE TO US TARIFFS                89

TABLE 23              VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,

2023–2030 (USD MILLION)            92

TABLE 24              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR CANINES, BY COUNTRY, 2023–2030 (USD MILLION)                 93

TABLE 25              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR FELINES, BY COUNTRY, 2023–2030 (USD MILLION)                 95

TABLE 26              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER ANIMALS,

BY COUNTRY, 2023–2030 (USD MILLION)               96

TABLE 27              VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            98

TABLE 28              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR LOKIVETMAB, BY COUNTRY, 2023–2030 (USD MILLION)            99

TABLE 29              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR BEDINVETMAB,

BY COUNTRY, 2023–2030 (USD MILLION)               100

TABLE 30              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR FRUNEVETMAB,

BY COUNTRY, 2023–2030 (USD MILLION)               101

TABLE 31              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR CANINE PARVOVIRUS MONOCLONAL ANTIBODY, BY COUNTRY, 2023–2030 (USD MILLION)               102

TABLE 32              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR GILVETMAB, BY COUNTRY, 2023–2030 (USD MILLION)            103

TABLE 33              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER PRODUCTS,

BY COUNTRY, 2023–2030 (USD MILLION)               103

TABLE 34              VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)            105

TABLE 35              COMMERCIALLY AVAILABLE MONOCLONAL ANTIBODIES WITH SUBCUTANEOUS ROUTE OF ADMINISTRATION          106

TABLE 36              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)               106

TABLE 37              COMMERCIALLY AVAILABLE MONOCLONAL ANTIBODIES WITH INTRAVENOUS ROUTE OF ADMINISTRATION          107

TABLE 38              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)     108

TABLE 39              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)     109

TABLE 40              VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA,

2023–2030 (USD MILLION)            111

TABLE 41              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               112

TABLE 42              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR PAIN MANAGEMENT,

BY COUNTRY, 2023–2030 (USD MILLION)               114

TABLE 43              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               115

TABLE 44              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            116

TABLE 45              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER THERAPY AREAS,

BY COUNTRY, 2023–2030 (USD MILLION)               117

TABLE 46              VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            119

TABLE 47              AVERAGE TOTAL AMOUNT SPENT PER HOUSEHOLD ON PETS IN US,

2023–2024 (USD)                119

TABLE 48              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY HOSPITALS/SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)               120

TABLE 49              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION)               122

TABLE 50              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)   124

TABLE 51              VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER END USERS,

BY COUNTRY, 2023–2030 (USD MILLION)               126

TABLE 52              VETERINARY MONOCLONAL ANTIBODIES MARKET, BY REGION,

2023–2030 (USD MILLION)            128

TABLE 53              NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT) 131

TABLE 54              NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 131

TABLE 55              NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ANIMAL TYPE, 2023–2030 (USD MILLION)       131

TABLE 56              NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               132

TABLE 57              NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 132

TABLE 58              NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY THERAPY AREA, 2023–2030 (USD MILLION)    133

TABLE 59              NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY END USER, 2023–2030 (USD MILLION)               133

TABLE 60              US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,

2023–2030 (USD MILLION)            134

TABLE 61              US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            134

TABLE 62              US: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 135

TABLE 63              US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA,

2023–2030 (USD MILLION)            135

TABLE 64              US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            135

TABLE 65              CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)            136

TABLE 66              CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            137

TABLE 67              CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 137

TABLE 68              CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            138

TABLE 69              CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            138

TABLE 70              EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (UNIT)              139

TABLE 71              EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION              140

TABLE 72              EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)            140

TABLE 73              EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            141

TABLE 74              EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 141

TABLE 75              EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            142

TABLE 76              EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            142

TABLE 77              GERMANY: KEY MACROECONOMIC INDICATORS      143

TABLE 78              GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)            143

TABLE 79              GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 144

TABLE 80              GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 144

TABLE 81              GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            145

TABLE 82              GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)                 145

TABLE 83              FRANCE: KEY MACROECONOMIC INDICATORS                 146

TABLE 84              FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)            146

TABLE 85              FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            147

TABLE 86              FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 147

TABLE 87              FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            148

TABLE 88              FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            148

TABLE 89              UK: KEY MACROECONOMIC INDICATORS                 149

TABLE 90              UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,

2023–2030 (USD MILLION)            149

TABLE 91              UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            150

TABLE 92              UK: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 150

TABLE 93              UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA,

2023–2030 (USD MILLION)            151

TABLE 94              UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            151

TABLE 95              ITALY: KEY MACROECONOMIC INDICATORS                 152

TABLE 96              ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE

2023–2030 (USD MILLION)            152

TABLE 97              ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            153

TABLE 98              ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 153

TABLE 99              ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            154

TABLE 100            ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            154

TABLE 101            SPAIN: KEY MACROECONOMIC INDICATORS                 155

TABLE 102            SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE

2023–2030 (USD MILLION)          155

TABLE 103            SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            156

TABLE 104            SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 156

TABLE 105            SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            157

TABLE 106            SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            157

TABLE 107            NETHERLANDS: KEY MACROECONOMIC INDICATORS      158

TABLE 108            NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ANIMAL TYPE, 2023–2030 (USD MILLION)       158

TABLE 109            NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               159

TABLE 110            NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 159

TABLE 111            NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY THERAPY AREA, 2023–2030 (USD MILLION)    160

TABLE 112            NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY END USER, 2023–2030 (USD MILLION)               160

TABLE 113            REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ANIMAL TYPE, 2023–2030 (USD MILLION)       161

TABLE 114            REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               161

TABLE 115            REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 162

TABLE 116            REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY THERAPY AREA, 2023–2030 (USD MILLION)    162

TABLE 117            REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY END USER, 2023–2030 (USD MILLION)               163

TABLE 118            ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY PRODUCT, 2023–2030 (UNIT)                165

TABLE 119            ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION 165

TABLE 120            ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ANIMAL TYPE, 2023–2030 (USD MILLION)       166

TABLE 121            ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               166

TABLE 122            ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 167

TABLE 123            ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY THERAPY AREA, 2023–2030 (USD MILLION)    167

TABLE 124            ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY END USER, 2023–2030 (USD MILLION)               168

TABLE 125            JAPAN: KEY MACROECONOMIC INDICATORS                 169

TABLE 126            JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,

2023–2030 (USD MILLION)            169

TABLE 127            JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            169

TABLE 128            JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 170

TABLE 129            JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            170

TABLE 130            JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            171

TABLE 131            CHINA: KEY MACROECONOMIC INDICATORS                 171

TABLE 132            CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,

2023–2030 (USD MILLION)            172

TABLE 133            CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            172

TABLE 134            CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 173

TABLE 135            CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            173

TABLE 136            CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            174

TABLE 137            INDIA: KEY MACROECONOMIC INDICATORS                 174

TABLE 138            INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,

2023–2030 (USD MILLION)            175

TABLE 139            INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            175

TABLE 140            INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 176

TABLE 141            INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            176

TABLE 142            INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            177

TABLE 143            AUSTRALIA: KEY MACROECONOMIC INDICATORS      177

TABLE 144            AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)            178

TABLE 145            AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 178

TABLE 146            AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 179

TABLE 147            AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            179

TABLE 148            AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)                 180

TABLE 149            SOUTH KOREA: KEY MACROECONOMIC INDICATORS      180

TABLE 150            SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ANIMAL TYPE, 2023–2030 (USD MILLION)       181

TABLE 151            SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 181

TABLE 152            SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 182

TABLE 153            SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY THERAPY AREA, 2023–2030 (USD MILLION)    182

TABLE 154            SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)                 183

TABLE 155            NEW ZEALAND: KEY MACROECONOMIC INDICATORS      183

TABLE 156            NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ANIMAL TYPE, 2023–2030 (USD MILLION)       184

TABLE 157            NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 184

TABLE 158            NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 185

TABLE 159            NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY THERAPY AREA, 2023–2030 (USD MILLION)    185

TABLE 160            NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)                 186

TABLE 161            REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ANIMAL TYPE, 2023–2030 (USD MILLION)       186

TABLE 162            REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               187

TABLE 163            REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 187

TABLE 164            REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY THERAPY AREA, 2023–2030 (USD MILLION)    188

TABLE 165            REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY END USER, 2023–2030 (USD MILLION)               188

TABLE 166            LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT) 189

TABLE 167            LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 190

TABLE 168            LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ANIMAL TYPE, 2023–2030 (USD MILLION)       190

TABLE 169            LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 191

TABLE 170            LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 191

TABLE 171            LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY THERAPY AREA, 2023–2030 (USD MILLION)    192

TABLE 172            LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)                 192

TABLE 173            BRAZIL: KEY MACROECONOMIC INDICATORS                 193

TABLE 174            BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)            193

TABLE 175            BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            194

TABLE 176            BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 194

TABLE 177            BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            195

TABLE 178            BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            195

TABLE 179            MEXICO: KEY MACROECONOMIC INDICATORS                 196

TABLE 180            MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)            196

TABLE 181            MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            197

TABLE 182            MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 197

TABLE 183            MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)            198

TABLE 184            MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2023–2030 (USD MILLION)            198

TABLE 185            REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ANIMAL TYPE, 2023–2030 (USD MILLION)       199

TABLE 186            REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               199

TABLE 187            REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 200

TABLE 188            REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY THERAPY AREA, 2023–2030 (USD MILLION)    200

TABLE 189            REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY END USER, 2023–2030 (USD MILLION)               201

TABLE 190            MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY PRODUCT, 2023–2030 (UNIT)                202

TABLE 191            MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ANIMAL TYPE, 2023–2030 (USD MILLION)       202

TABLE 192            MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               203

TABLE 193            MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)                 203

TABLE 194            MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY THERAPY AREA, 2023–2030 (USD MILLION)    204

TABLE 195            MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY END USER, 2023–2030 (USD MILLION)               204

TABLE 196            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET                 205

TABLE 197            VETERINARY MONOCLONAL ANTIBODIES MARKET:

DEGREE OF COMPETITION, 2024               208

TABLE 198            VETERINARY MONOCLONAL ANTIBODIES MARKET: REGION FOOTPRINT 214

TABLE 199            VETERINARY MONOCLONAL ANTIBODIES MARKET: ANIMAL TYPE FOOTPRINT      215

TABLE 200            VETERINARY MONOCLONAL ANTIBODIES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT      215

TABLE 201            VETERINARY MONOCLONAL ANTIBODIES MARKET: THERAPY AREA FOOTPRINT  216

TABLE 202            VETERINARY MONOCLONAL ANTIBODIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES         218

TABLE 203            VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES              218

TABLE 204            VETERINARY MONOCLONAL ANTIBODIES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025  219

TABLE 205            VETERINARY MONOCLONAL ANTIBODIES MARKET: DEALS,

JANUARY 2022–JUNE 2025              220

TABLE 206            VETERINARY MONOCLONAL ANTIBODIES MARKET: EXPANSIONS,

JANUARY 2022–JUNE 2025              221

TABLE 207            ZOETIS SERVICES LLC: COMPANY OVERVIEW                 222

TABLE 208            ZOETIS SERVICES LLC: PRODUCTS OFFERED                 223

TABLE 209            ZOETIS SERVICES LLC: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022−JUNE 2025            224

TABLE 210            ZOETIS SERVICES LLC: DEALS, JANUARY 2022−JUNE 2025                225

TABLE 211            ELANCO: COMPANY OVERVIEW                227

TABLE 212            ELANCO: PRODUCTS OFFERED 228

TABLE 213            ELANCO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022−JUNE 2025 229

TABLE 214            ELANCO: EXPANSIONS, JANUARY 2022−JUNE 2025        229

TABLE 215            MERCK & CO., INC.: COMPANY OVERVIEW                 231

TABLE 216            MERCK & CO., INC.: PRODUCTS OFFERED                 232

TABLE 217            MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022−JUNE 2025            233

TABLE 218            MERCK & CO., INC.: EXPANSIONS, JANUARY 2022−JUNE 2025                233

TABLE 219            ANIMAB: COMPANY OVERVIEW                235

TABLE 220            ANIMAB: PRODUCTS OFFERED 235

TABLE 221            ANIMAB: DEALS, JANUARY 2022−JUNE 2025                 236

TABLE 222            VAXXINOVA INTERNATIONAL B.V.: COMPANY OVERVIEW          237

TABLE 223            CEVA LOGISTICS: COMPANY OVERVIEW                 238

TABLE 224            MABGENESIS INC.: COMPANY OVERVIEW                 239

TABLE 225            DECHRA: COMPANY OVERVIEW                240

TABLE 226            BIOGENESIS BAGO: COMPANY OVERVIEW                 241

TABLE 227            BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW    242

TABLE 228            VIRBAC: COMPANY OVERVIEW 243

TABLE 229            BIOVETA, A.S.: COMPANY OVERVIEW     244

TABLE 230            NIPPON ZENYAKU KOGYO CO., LTD.: COMPANY OVERVIEW          245

LIST OF FIGURES

FIGURE 1              VETERINARY MONOCLONAL ANTIBODIES MARKET SEGMENTATION

AND REGIONAL SCOPE 26

FIGURE 2              VETERINARY MONOCLONAL ANTIBODIES MARKET: YEARS CONSIDERED  28

FIGURE 3              VETERINARY MONOCLONAL ANTIBODIES MARKET: RESEARCH DESIGN     29

FIGURE 4              VETERINARY MONOCLONAL ANTIBODIES MARKET: KEY PRIMARY SOURCES            32

FIGURE 5              VETERINARY MONOCLONAL ANTIBODIES MARKET: INSIGHTS FROM PRIMARIES   33

FIGURE 6              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS     33

FIGURE 7              BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION                34

FIGURE 8              BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION                 34

FIGURE 9              VETERINARY MONOCLONAL ANTIBODIES MARKET SIZE ESTIMATION:

SUPPLY-SIDE ANALYSIS, 2024      35

FIGURE 10            MONOCLONAL ANTIBODIES IN ANIMAL HEALTH: MARKET SIZE ESTIMATION     36

FIGURE 11            TOP-DOWN APPROACH                38

FIGURE 12            BOTTOM-UP APPROACH              38

FIGURE 13            VETERINARY MONOCLONAL ANTIBODY MARKET: CAGR PROJECTIONS  39

FIGURE 14            DATA TRIANGULATION METHODOLOGY                 40

FIGURE 15            VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,

2025 VS. 2030 (USD MILLION)      43

FIGURE 16            VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,

2025 VS. 2030 (USD MILLION)      44

FIGURE 17            VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)            44

FIGURE 18            VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA,

2025 VS. 2030 (USD MILLION)      45

FIGURE 19            VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      46

FIGURE 20            GEOGRAPHICAL SNAPSHOT OF VETERINARY MONOCLONAL ANTIBODIES MARKET   47

FIGURE 21            INCREASING PREVALENCE OF CHRONIC AND ACUTE DISEASES TO DRIVE MARKET     48

FIGURE 22            CANINES SEGMENT AND US LED NORTH AMERICA MARKET IN 2024           49

FIGURE 23            CANINES SEGMENT TO CAPTURE LARGEST MARKET SHARE DURING FORECAST PERIOD     49

FIGURE 24            LOKIVETMAB (CYTOPOINT) SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD                50

FIGURE 25            SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD                 50

FIGURE 26            DERMATOLOGY SEGMENT TO HAVE LARGEST MARKET SHARE DURING FORECAST PERIOD     51

FIGURE 27            FRANCE TO REGISTER HIGHEST GROWTH IN VETERINARY MONOCLONAL ANTIBODIES MARKET FROM 2025 TO 2030                 52

FIGURE 28            VETERINARY MONOCLONAL ANTIBODIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    53

FIGURE 29            NEW REVENUE POCKETS FOR PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET       61

FIGURE 30            VETERINARY MONOCLONAL ANTIBODIES MARKET: SUPPLY CHAIN ANALYSIS         64

FIGURE 31            VETERINARY MONOCLONAL ANTIBODIES MARKET: ECOSYSTEM ANALYSIS              65

FIGURE 32            VETERINARY MONOCLONAL ANTIBODIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2020–2024                 66

FIGURE 33            VETERINARY MONOCLONAL ANTIBODIES MARKET: PATENT ANALYSIS,

JANUARY 2014–MAY 2025               69

FIGURE 34            TOP APPLICANTS FOR VETERINARY MONOCLONAL ANTIBODIES PATENTS,

JANUARY 2014–MAY 2025               70

FIGURE 35            VETERINARY MONOCLONAL ANTIBODIES MARKET: PORTER’S FIVE FORCES ANALYSIS       78

FIGURE 36            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER                80

FIGURE 37            KEY BUYING CRITERIA, BY END USER    81

FIGURE 38            VETERINARY MONOCLONAL ANTIBODIES MARKET: AI USE CASES 86

FIGURE 39            NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET SNAPSHOT            130

FIGURE 40            ASIA PACIFIC: DOG POPULATION GROWTH, BY COUNTRY, 2024 164

FIGURE 41            ASIA PACIFIC: CAT POPULATION GROWTH, BY COUNTRY, 2024 164

FIGURE 42            REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET, 2023–2024              207

FIGURE 43            VETERINARY MONOCLONAL ANTIBODIES MARKET SHARE ANALYSIS, 2024                 208

FIGURE 44            US: VETERINARY MONOCLONAL ANTIBODIES MARKET SHARE ANALYSIS, 2024                 208

FIGURE 45            RANKING OF KEY PLAYERS IN VETERINARY MONOCLONAL

ANTIBODIES MARKET, 2024         209

FIGURE 46            VETERINARY MONOCLONAL ANTIBODIES MARKET:

BRAND/PRODUCT COMPARISON             210

FIGURE 47            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                211

FIGURE 48            EV/EBITDA OF KEY VENDORS   211

FIGURE 49            VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024                 213

FIGURE 50            VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY FOOTPRINT             214

FIGURE 51            VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024        217

FIGURE 52            ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2024)    223

FIGURE 53            ELANCO: COMPANY SNAPSHOT (2024)  228

FIGURE 54            MERCK & CO., INC.: COMPANY SNAPSHOT (2024)    232

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧